Iniciar Sesión Regístrate abrir menu

Bibliografía Científica

Artículos por temáticas

En este apartado encontrará una actualización mensual de Enfermedad de Alzheimer y Demencias

8233 ARTÍCULOS , VIENDO DEL 4171 AL 4185

Integrating Omic Technologies in Alzheimer's Disease

Avramouli A, Vlamos PM.

Adv Exp Med Biol. 2017;987:177-184. doi: 10.1007/978-3-319-57379-3_16.

Acetylcholinesterase Inhibitors: Beneficial Effects on Comorbidities in Patients With Alzheimer's Disease

Kaushik V, Smith ST, Mikobi E, Raji MA.

Am J Alzheimers Dis Other Demen. 2018 Mar;33(2):73-85. doi: 10.1177/1533317517734352. Epub 2017 Oct 3.

The present and future of pharmacotherapy of Alzheimer's disease: A comprehensive review

Anand A, Patience AA, Sharma N, Khurana N.

Eur J Pharmacol. 2017 Nov 15;815:364-375. doi: 10.1016/j.ejphar.2017.09.043. Epub 2017 Oct 1.

Astroglial Connexins as a Therapeutic Target for Alzheimer's Disease

Yi C, Koulakoff A, Giaume C.

Curr Pharm Des. 2017;23(33):4958-4968. doi: 10.2174/1381612823666171004151215.

Research advances in the treatment of Alzheimer's disease with polysaccharides from traditional Chinese medicine

Liu Q, Wang SC, Ding K.

Chin J Nat Med. 2017 Sep;15(9):641-652. doi: 10.1016/S1875-5364(17)30093-6.

β-Amyloid and the Pathomechanisms of Alzheimer's Disease: A Comprehensive View

Penke B, Bogár F, Fülöp L.

Molecules. 2017 Oct 10;22(10):1692. doi: 10.3390/molecules22101692.

Aβ Peptide Originated from Platelets Promises New Strategy in Anti-Alzheimer's Drug Development

Inyushin MY, Sanabria P, Rojas L, Kucheryavykh Y, Kucheryavykh L.

Biomed Res Int. 2017;2017:3948360. doi: 10.1155/2017/3948360. Epub 2017 Sep 5.

Curcumin or bisdemethoxycurcumin for nose-to-brain treatment of Alzheimer disease? A bio/chemo-informatics case study

Hathout RM, El-Ahmady SH, Metwally AA.

Nat Prod Res. 2018 Dec;32(24):2873-2881. doi: 10.1080/14786419.2017.1385017. Epub 2017 Oct 12.

Genetic and Pharmacological Discovery for Alzheimer's Disease Using Caenorhabditis elegans

Griffin EF, Caldwell KA, Caldwell GA.

ACS Chem Neurosci. 2017 Dec 20;8(12):2596-2606. doi: 10.1021/acschemneuro.7b00361. Epub 2017 Oct 25.

Resveratrol and Amyloid-Beta: Mechanistic Insights

Jia Y, Wang N, Liu X.

Nutrients. 2017 Oct 14;9(10):1122. doi: 10.3390/nu9101122.

The potential of solanezumab and gantenerumab to prevent Alzheimer's disease in people with inherited mutations that cause its early onset

Panza F, Seripa D, Lozupone M, Solfrizzi V, Imbimbo BP, Barulli MR, Tortelli R, Capozzo R, Bisceglia P, Dimitri A, Stallone R, Dibello V, Quaranta N, Daniele A, Bellomo A, Greco A, Logroscino G.

Expert Opin Biol Ther. 2018 Jan;18(1):25-35. doi: 10.1080/14712598.2018.1389885. Epub 2017 Oct 16.

Molecular and Cellular Mechanisms of Sporadic Alzheimer's Disease: Studies on Rodent Models in vivo

Gulyaeva NV, Bobkova NV, Kolosova NG, Samokhin AN, Stepanichev MY, Stefanova NA.

Biochemistry (Mosc). 2017 Oct;82(10):1088-1102. doi: 10.1134/S0006297917100029.

Adiponectin and sporadic Alzheimer's disease: Clinical and molecular links

Letra L, Rodrigues T, Matafome P, Santana I, Seiça R.

Front Neuroendocrinol. 2019 Jan;52:1-11. doi: 10.1016/j.yfrne.2017.10.002. Epub 2017 Oct 13.

Can small molecule inhibitors of glutaminyl cyclase be used as a therapeutic for Alzheimer's disease?

Wu H.

Future Med Chem. 2017 Nov;9(17):1979-1981. doi: 10.4155/fmc-2017-0190. Epub 2017 Oct 27.

How efficient are rodent models for Alzheimer's disease drug discovery?

Guo B, Zhou Q.

Expert Opin Drug Discov. 2018 Feb;13(2):113-115. doi: 10.1080/17460441.2018.1398730. Epub 2017 Oct 31.

Actualización mensual Regístrese para recibir los avisos de actualización

Si quiere recomendar un artículo/publicación para completar este apartado puede hacerlo a través del formulario de contacto para su valoración.

En ningún caso la información facilitada constituye asesoramiento por parte de Zambon

Con el aval de:

Logo SEN Logo WIS

En colaboración con:

Zambon Neurociencias